12:00 AM
 | 
Jan 02, 2012
 |  BC Week In Review  |  Clinical News  |  Regulatory

Sativex regulatory update

Sweden's Medical Products Agency approved GW Pharma's Sativex to treat moderate to severe spasticity due to multiple sclerosis (MS) in patients who have not responded adequately to other medications. Last year, Sativex was recommended for approval in 6 countries, including Sweden, under the EU...

Read the full 196 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >